MidWest Drug Development Conference
ONLINE EVENT | Oct. 4-5, 2021
2021-10-04 08:00:00
Register!
Downloads
  • 2021 Program
  • Flyer
  • 2021 Schedule
  • 2019 Program
  • 2018 Program
  • Map & Other Info (Coming soon!)
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact

ProGel delivers meds for long-term local effect

Ensign Pharmaceutical (University of Nebraska Medical Center)

ProGel is a platform technology with a diverse spectrum of drug payloads, such as steroids, statins, antioxidants, opioids, chemotherapeutics, and hormones.  Ensign Pharmaceutical’s initial product focuses on managing osteoarthritis pain, incorporating a potent steroid, dexamethasone, into the formulation.

When injected into a joint, dexamethasone provides temporary relief of debilitating pain and swelling caused by osteoarthritis, a chronic condition that slowly erodes the protective cartilage at the end of bones.

While effective for pain relief, the benefit of dexamethasone is unfortunately short-lived, usually lasting only a few days. However, when formulated with ProGel, dexamethasone has the potential to remain active much longer, potentially providing relief for months. In addition to providing a more sustained and stable local release of medication, the hydrogel also has the benefit of limiting potential harmful side effects, including weight gain, increased blood sugar, insomnia and osteoporosis.

A liquid at lower temperatures, ProGel transforms into a gel-like substance as it reaches body temperature. The gel is then more likely to linger in the affected area, concentrating the pharmaceutical payload exactly where it needs to be.

Any number of pharmaceuticals can combine with ProGel, for localized and sustained delivery of a variety of therapeutic agents. For example, ProGel could help treat other musculoskeletal disorders such as chronic back pain, tendonitis, bursitis, fracture repair, spinal fusion, and periodontal bone regeneration.

It may also serve as a depot for sustained drug delivery in a broad spectrum of disorders, including hormone therapy for high-risk pregnancy, and localized chemotherapy.

Learn more at www.ensignpharmaceutical.com.

Logo

MIDWEST DRUG DEVELOPMENT CONFERENCE
Bringing together industry and the best university drug development researchers in the Midwest
An Online Event
Oct. 4-5, 2021

Latest News
  • Presentation schedule set for 2021 September 21, 2021
  • MWDD moves to a virtual event in 2021 August 17, 2021
  • Sponsorship, presentation slots nearly full July 29, 2021
  • Registrations are now open for 2021 March 25, 2021
Twitter Hightlights
  • Today's the day!
    491 days ago
  • Schedule is set for the 2021 MidWest Drug Development Conference. Register today! https://t.co/5SvzL4EhuV
    504 days ago
  • No surprise to see some incredible innovations out of @UWMadison that could change drug delivery approaches, cancer… https://t.co/h90yfHwC5k
    505 days ago

Follow us! @DrugMw